Literature DB >> 12794760

Exclusion of BRAFV599E as a melanoma susceptibility mutation.

Peter Meyer1, Ruediger Klaes, Christina Schmitt, Melanie Barbara Boettger, Claus Garbe.   

Abstract

Very recently, BRAF mutations were found in about 2/3 of malignant melanomas and at lower frequencies in other human cancers. The BRAF gene codes for a protein in the mitogen-activated protein kinase (MAPK) pathway. All mutations identified to date are within the kinase domain, with a single missense mutation (V599E) accounting for 80%. We investigated the hypothesis that this common somatic BRAF mutation (V599E) would contribute to melanoma predisposition in familial and polygenic malignant melanoma if occurring as a germ-line mutation. We performed comprehensive mutational screening of exon 15 of BRAF using DHPLC (denaturing high-performance liquid chromatography) and DNA sequencing techniques. No V599E mutation could be detected in 172 melanoma patients comprising 46 familial cases, 21 multiple melanoma patients and 106 cases with at least one first-degree relative suffering from other cancers. We therefore conclude that the common somatic BRAF mutation V599E does not contribute to polygenic and familial melanoma predisposition. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12794760     DOI: 10.1002/ijc.11199

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases.

Authors:  Arati Sharma; Melissa A Tran; Shile Liang; Arun K Sharma; Shantu Amin; Charles D Smith; Cheng Dong; Gavin P Robertson
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

2.  Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas.

Authors:  Jie Zhang; Tsun-Wen Yao; Rintaro Hashizume; Sujatmi Hariono; Krister J Barkovich; Qi-Wen Fan; Michael Prados; C David James; William A Weiss; Theodore Nicolaides
Journal:  J Neurooncol       Date:  2016-11-15       Impact factor: 4.130

3.  Association between single-nucleotide polymorphisms of BRAF and papillary thyroid carcinoma in a Chinese population.

Authors:  Qiang Zhang; Fangfang Song; Hong Zheng; Xiaoling Zhu; Fengju Song; Xiaofeng Yao; Lun Zhang; Kexin Chen
Journal:  Thyroid       Date:  2013-01       Impact factor: 6.568

4.  Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

Authors:  Mitchell Cheung; Arati Sharma; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

5.  DNA fingerprinting of glioma cell lines and considerations on similarity measurements.

Authors:  Pierre Bady; Annie-Claire Diserens; Vincent Castella; Stefanie Kalt; Karl Heinimann; Marie-France Hamou; Mauro Delorenzi; Monika E Hegi
Journal:  Neuro Oncol       Date:  2012-05-08       Impact factor: 12.300

6.  Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases.

Authors:  Martin Deichmann; Marianne Thome; Axel Benner; Martin Kirschner; Judith Hassanzadeh; Hjalmar Kurzen
Journal:  BMC Cancer       Date:  2005-06-03       Impact factor: 4.430

7.  Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame.

Authors:  Marijke van Rikxoort; Martin Michaelis; Markus Wolschek; Thomas Muster; Andrej Egorov; Joachim Seipelt; Hans Wilhelm Doerr; Jindrich Cinatl
Journal:  PLoS One       Date:  2012-05-01       Impact factor: 3.240

8.  Polymorphisms of the BRAF gene predispose males to malignant melanoma.

Authors:  Peter Meyer; Consolato Sergi; Claus Garbe
Journal:  J Carcinog       Date:  2003-11-14

9.  B-Raf specific antibody responses in melanoma patients.

Authors:  Joachim Fensterle; Jürgen C Becker; Tamara Potapenko; Veronika Heimbach; Claudia S Vetter; Eva B Bröcker; Ulf R Rapp
Journal:  BMC Cancer       Date:  2004-09-12       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.